PD-1 Blockers

Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung ca...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cell Ročník 162; číslo 5; s. 937
Hlavní autor:	Wolchok, Jedd D
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 27.08.2015
Témata:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Clinical Trials as Topic Humans Lung Neoplasms - drug therapy Melanoma - drug therapy Programmed Cell Death 1 Receptor - antagonists & inhibitors Skin Neoplasms - drug therapy
ISSN:	1097-4172, 1097-4172
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1097-4172 1097-4172
DOI:	10.1016/j.cell.2015.07.045